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ADAM15 mediates upregulation 
of Claudin-1 expression in breast 
cancer cells
Jens Mattern1, Christian S. Roghi3,4, Melanie Hurtz1,5, Vera Knäuper  2, Dylan R. edwards  3 
& Zaruhi Poghosyan  1
A Disintegrin and Metalloproteinase-15 (ADAM15) is a transmembrane protein involved in protein 
ectodomain shedding, cell adhesion and signalling. We previously cloned and characterised 
alternatively spliced variants of ADAM15 that differ in their intracellular domains and demonstrated 
correlation of the expression of specific variants with breast cancer prognosis. In this study we have 
created isogenic cell panels (MDA-MB-231 and MCF-7) expressing five ADAM15 variants including wild-
type and catalytically inactive forms. The expression of ADAM15 isoforms in MDA-MB-231 cells led 
to cell clustering to varying degree, without changes in EMT markers vimentin, slug and E-cadherin. 
Analysis of tight junction molecules revealed ADAM15 isoform specific, catalytic function dependent 
upregulation of Claudin-1. The expression of ADAM15A, and to a lesser degree of C and E isoforms led to 
an increase in Claudin-1 expression in MDA-MB-231 cells, while ADAM15B had no effect. In MCF-7 cells, 
ADAM15E was the principal variant inducing Claudin-1 expression. Sh-RNA mediated down-regulation 
of ADAM15 in ADAM15 over-expressing cells reduced Claudin-1 levels. Additionally, downregulation 
of endogenous ADAM15 expression in T47D cells by shRNA reduced endogenous Claudin-1 expression 
confirming a role for ADAM15 in regulating Claudin-1 expression. The PI3K/Akt/mTOR pathway was 
involved in regulating Claudin-1 expression downstream of ADAM15. Immunofluorescence analysis of 
MDA-MB-231 ADAM15A expressing cells showed Claudin-1 at cell-cell junctions, in the cytoplasm and 
nuclei. ADAM15 co-localised with Claudin-1 and ZO1 at cell-cell junctions. Immunoprecipitation analysis 
demonstrated complex formation between ADAM15 and ZO1/ZO2. These findings highlight the 
importance of ADAM15 Intra Cellular Domain-mediated interactions in regulating substrate selection 
and breast cancer cell phenotype.
The ADAM (a metalloproteinase and a disintegrin) family of transmembrane and secreted metalloproteinases 
perform important functions in cell adhesion and signalling, primarily through the regulated ectodomain shed-
ding of ligands and receptors for multiple pathways such as those controlled by the epidermal growth factor 
receptor and Notch1,2. ADAM15 shares the multi-domain organisation of other family members, containing met-
alloproteinase (MP), disintegrin (dis), cysteine-rich and EGF-like domains, which are connected via a transmem-
brane helix to the intracellular domain (ICD)3. The ADAM15 ICD contains tyrosines that when phosphorylated 
interact with SH2 domain containing proteins, and includes specific proline-rich regions that act as ligands for 
several SH3 domain containing proteins4,5. Additionally, we have shown that some of the interactions between 
ADAM15 and SH3 domain containing proteins depend on the phosphorylation status of the ADAM15 ICD4.
ADAM15 pre-mRNA is subject to complex alternative splicing in normal tissues and cancer cells leading 
to inclusion or exclusion of exons 18 to 23. As a result 13 isoforms of ADAM15 protein arise, that vary by the 
number and nature of their proline-rich regions, affecting ADAM15 ICD-mediated intracellular protein-protein 
interactions5,6. Previously we have shown that differential expression of ADAM15 spliced isoforms has prognostic 
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significance in breast cancer patients5. In particular, the expression of ADAM15A/B isoforms correlate with poor 
prognosis in node-negative breast cancer patients, while the expression of ADAM15C correlates with better prog-
nosis in node-positive disease5.
ADAM15 is catalytically active and has been shown to shed several transmembrane proteins such as CD237, 
pro-amphiregulin and pro-HB-EGF8, E-cadherin9, MICB10, FGFR2IIIb11. Interestingly, we have shown that the 
shedding of FGFR2IIIb is ADAM15 isoform- and phosphorylation-dependent, with ADAM15B shedding effi-
ciency enhanced through Src-dependent phosphorylation12.
To better understand how ADAM15 isoforms affect breast cancer prognosis, we have established two isogenic 
cell panels expressing individual ADAM15 isoforms in either the aggressive triple negative breast cancer cell 
line MDA-MB-231 or the less aggressive MCF7 cell line utilising the Invitrogen FLP-in system. This ensures that 
any changes observed in cell behaviour within the panel depend only on the ADAM15 isoform expressed and 
excludes gene copy number or integration artefacts. We show for the first time ADAM15 isoform-, and catalytic 
function-dependent upregulation of Claudin-1 expression, which may be responsible for the effects of ADAM15 
on cancer cell phenotypes and prognostic outcomes for breast cancer patients.
Materials and Methods
Cell lines. The following cell lines and their derivatives were used in the study: Breast cancer cell lines 
MDA-MB-231, MCF7/FRT, MCF7/FRT, T47D, squamous cell carcinoma cell line A431, human embryonic kid-
ney cell line HEK293FT. Cells were kept in culture up to three months after thawing. Cells were tested for myco-
plasma by PCR analysis every 4–6 months. Selected cell lines were authenticated in 2014 by DNA Diagnostic 
Center (MDA-MB-231 and derivatives), and in 2018 by Eurofins (MCF7/FRT, T47D and derivatives).
Generation of MDA-MB-231/FRT cells, and an isogenic ADAM15 expression panel. The 
Invitrogen Flp-In- system (Invitrogen K601001) was used to generate the isogenic cell panel expressing ADAM15 
isoforms. Briefly, MDA-MB-231 cells were transfected with ScaI linearised pFRT/lacZeo plasmid using 
Lipofectamine 2000 (Invitrogen 11668019). Zeocin-resistant clones were isolated and screened for single inte-
gration sites by Southern Blot analysis, followed by low-coverage whole genome sequencing (BGI, Beijing). The 
validated MDA-MB-231 clone containing a single recombination site was co-transfected with pOG44, expressing 
Flp recombinase, and pcDNA5/FRT-V5-His plasmids encoding the ADAM15 WT and E349A isoforms. These 
plasmids were created by sub cloning the ADAM15 sequences from pcDNA4-V5/His ADAM15 expression plas-
mids5 using HindIII and XhoI into pcDNA5/FRT-V5-His vector. The cells were selected in DMEM containing 
1 mg/ml Hygromycin B (Invitrogen).
MTS proliferation assay. Cells were seeded in triplicates into four 96-well plates with 3 × 103 cells per well 
in 100 µL volume. At indicated time points 20 µL of CellTiter 96 AQueous One Solution (Promega G3580) was 
added to each well and incubated for 4 h at 37 °C. The absorbance was measured at 450 nm. The measurement 
after 24 h was considered as 1.
Demethylation and deacetylation. Cells were treated with 50 µM Decitabine (5-aza-2′-deoxycytidine) 
for three days, each day replacing the media and adding Decitabine fresh. On the third day, 500 nM Trichostatin 
A was added, and cells were lysed the following day.
Flow cytometric analysis of cell size. Trypsinised cells were stained with 10 µg/ml propidium iodide and 
analysed by Accuri C6 flow cytometre. The median size was automatically calculated by FlowJo. For comparison, 
a scatter plot was generated and one-way ANOVA was performed.
Microscopic determination of cell spread area. Phase-contrast images were taken at 200 x magnifica-
tion and quantified with ImageJ. For each cell line five images of random positions were taken using an EVOS XL 
core imaging system (Thermo Fisher Scientific). This was done for three different passages to achieve 15 images. 
In each picture ten representative cells were chosen and the cell area was outlined and measured. This led to 150 
measured cells for each cell line. For statistical analysis Bartlett’s test for equal variances was used to determine 
the significance. As follow-up test Dunnett’s multiple comparison test was used. The results are presented as a 
box-and-whiskers plot.
Immunoprecipitation. Cells were lysed in RIPA buffer supplemented with proteinase and phosphatase 
inhibitors (Roche) and 10 mM phenanthroline (Sigma), and quantified using the BCA kit (Thermo Fisher). 
500 µg/ml of total protein extract was used per IP. ADAM15 was IP-ed with α-V5 affinity gel (Sigma). For all 
other IPs Protein G sepharose was used together with respective antibodies. SDS-PAGE and Western Blotting 
were carried out using standard protocols.
Scratch-wound assay. Cells were seeded into 6 cm dishes and grown until confluent. Wounds were intro-
duced with a white tip (10 µL). Pictures were taken at 0, then at 8, 24, 32 and 48 hrs using an EVOS XL core 
cell imaging system (Thermo Fisher Scientific). Analysis was carried out with the MRI wound healing tool for 
ImageJ. The 0 h time points were normalised to 100% and the wound closure was calculated using Microsoft 
Excel. Statistical analysis was carried out with 2-way ANOVA and Bonferroni post-test in GraphPad Prism 5.01. 
ADAM15 isoform expressing cells were compared to the parental cell line MDA-MB-231/FRT.
Immunostaining and confocal microscopy. Cells were seeded onto glass cover slips preincubated in 
complete growth media and grown for 72 hrs. Cells were washed with PBS, fixed 4% formaldehyde for 20 min, 
washed in PBS, then permeabilised with 0.1% saponin/PBS for 2 min. After further washes with PBS, cells were 
3Scientific RepoRtS |         (2019) 9:12540  | https://doi.org/10.1038/s41598-019-49021-3
www.nature.com/scientificreportswww.nature.com/scientificreports/
blocked for 30 min in 1% BSA in PBS. Afterwards, the cells were incubated with the primary antibodies overnight 
at 4 °C in a humidified chamber. After further washes with PBS, corresponding Alexa conjugates were added in 
the blocking buffer for 1 hr. Excess antibodies were washed off with PBS, and the cover slips were mounted on 
microscope slides using Prolong Gold mounting media with DAPI (Invitrogen). Slides were analysed using a 
Leica SP5 confocal microscope (Leica, Microsystems) and images acquired with a 63x oil immersion objective.
Lentiviral particle production and shRNA-mediated downregulation. pLKO.1/puro-
mycin plasmids encoding Mission shRNA (Sigma) sequences were used (table  4 in Supplementary 
Information).  Additionally,  an shRNA sequence targeting the 3 ′  UTR of ADAM15: FWD 
5′-CCGGGTTGGACGGGATTGAGGAACTCGAGTTCCTCAATCCCGTCCAACTTTTTG-3′  REV 
5′-AATTCAAAAAGTTGGACGGGATTGAGGAACTCGAGTTCCTCAATCCCGTCCAAC-3′, was cloned into 
pLKO.1 using AgeI and EcorRI restriction sites. The positive clones were selected by XhoI digest according to 
Sigma Mission shRNA protocol. Lentiviral particles were produced according to Sigma Mission shRNA protocol. 
Stable downregulation of Claudin-1 or ADAM15 was achieved by 1 µg/mL puromycin selection.
RNA extraction, RT-PCR and qPCR. Qiagen QIAshredder (Qiagen 79654), RNeasy Kit (Qiagen 
74104) and Superscript II (Invitrogen 18064014) were used to extract RNA and perform RT. KAPA 2G Robust 
Hot Start ready PCR mix (KAPA Biosystems KK5702) was used to amplify Claudin-1 and GAPDH (Table 5 
in Supplementary information). qPCR by Taqman analysis for claudin-1 expression was performed using 
Hs00221623_M1 primer and probe set (Thermo Fisher Scientific).
Results
Generation of an isogenic panel expressing proteolytically active and inactive ADAM15 iso-
forms in MDA-MB-231 cells. Alternatively-spliced ADAM15 isoforms (Fig. 1a) have prognostic sig-
nificance in breast cancer, implying that the isoforms affect cell behaviour differently5. To elucidate the role of 
ADAM15 isoforms in breast cancer progression, we generated an isogenic cell panel expressing each ADAM15 
isoform in MDA-MB-231 cells. To achieve that, we introduced an FRT site for the FLP recombinase into 
MDA-MB-231 cells, and selected a clone containing a single integration site. The selected MDA-MB-231/FRT 
clone was confirmed by next-generation sequencing to contain a single integration site on chromosome 4 within 
the intron separating exons 5 and 6 of the FAM190A gene. Analysis of the endogenous expression levels of indi-
vidual ADAM15 isoforms in this clone by qPCR demonstrated the presence of predominantly ADAM15A iso-
form (Supplementary Fig. 1a).
We used this MDA-MB-231/FRT clone to co-transfect with the pOG44 plasmid encoding the FLP recom-
binase together with pcDNA5/FRT plasmids encoding the five main ADAM15 isoforms in both WT and 
catalytically-dead E349A versions, each of which carried a C-terminal V5-His tag for detection (Fig. 1b). The 
presence of the ADAM15 cassettes had no effect on expression of the host FAM190A gene (Supplementary 
Figure 1b).
In the isogenic panel of MDA-MB-231/FRT cell lines we noted some variation in the levels of expression of the 
isoforms, with slightly higher expression of WT ADAM15A and ADAM15B, and lower levels of WT ADAM15C 
and ADAM15D isoforms (Fig. 1b). We asked if differential methylation is responsible for varying expression 
levels of ADAM15 isoforms. Treatment of cells with DNA demethylating agent Decitabine led to an increase in 
the expression levels of ADAM15, which was further enhanced by a combined treatment with HDAC inhibitor 
trichostatinA, validating that the decreased expression of some isoforms is due to epigenetic suppression (Fig. 1c). 
For comparison, we also generated an isogenic cell panel expressing ADAM15 isoforms in MCF7/FRT cells13. 
The expression level of ADAM15 isoforms within the MCF7 panel was nearly equal in this series, though again 
ADAM15D showed the lowest steady-state level (Fig. 1d).
Expression of ADAM15 isoforms affects cell morphology, proliferation and migration. The 
expression of ADAM15 isoforms led to morphological changes in MDA-MB-231 cells (Fig. 2). In general, we 
observed a tendency of cell clustering of varying degree with most wild type (WT) ADAM15 isoforms (Fig. 2a), 
with the exception of ADAM15B. This clustering effect was most prominent for ADAM15A expressing cells, 
which grew in epithelial-like islands. To further examine these observed morphological changes were due to 
ADAM15, we introduced shRNA targeting the coding region of ADAM15 into MDA-MB-231/ADAM15A 
cells, which resulted in substantial suppression of ADAM15 expression and reverted the epithelial-like pheno-
type attributable to ADAM15A-expression (Fig. 2b). Additionally, overexpression of all WT ADAM15 isoforms 
increased cell circularity (Fig. 2c), with the expression of ADAM15C and E isoforms resulting in an increase in 
cell spreading and size (Fig. 2d,e). In the MCF7/ADAM15 cell panel there were less dramatic morphological 
changes, as all of the lines grew in a similar fashion to parental MCF7 cells (Supplementary Fig. 2). However, 
there were subtle changes in that ADAM15D expressing MCF7 cells were smaller than all others, and ADAM15E 
MCF7 cells had altered cell-cell junctions with visible gapping between the cells, bridged by membrane projec-
tions, apparent in the higher magnification images in Supplementary Fig. 2.
Focussing on the MDA-MB-231 cell panel, we tested whether ADAM15 isoforms may affect cell viability 
and the potential requirement for proteolytic activity by comparing the growth rates of the cells expressing WT 
and catalytically inactive ADAM15 isoforms using an MTS assay (Fig. 3a). The expression of ADAM15A, D 
and E WT as well as their catalytically inactive E349A counterparts reduced the growth rate of MDA-MB-231 
cells at 96hrs, while the expression of ADAM15C reduced the growth rate of MDA-MB-231 cells in a catalytic 
function-dependent manner. The expression of ADAM15B (WT or inactive) had no effect on growth rate. 
Additional Western blot analysis confirmed that ADAM15 isoforms were processed to their respective active 
forms in these cells (Suppl. Fig. 1C). Comparison of the growth rate of MCF7 cells expressing ADAM15 isoforms 
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did not reveal any significant differences, highlighting the relevance of cell context for the effects of ADAM15 
(data not shown).
Previously it has been shown that ADAM15 either reduces or increases cell motility depending on the cell 
type14–17. To evaluate the influence of the individual ADAM15 isoforms on cell motility in the MDA-MB-231/FRT 
panel, we performed scratch wound assays (Fig. 3b,c). The ADAM15 isoforms, with the exception of ADAM15E, 
reduced healing of the cell monolayers significantly.
In summary, the morphological changes observed in MDA-MB-231 and MCF7 ADAM15 expressing cells 
were catalytic function-dependent, while the reduction in the growth rate of MDA-MB-231 cells depended on the 
catalytic activity of only ADAM15C isoform expressing cells.
Figure 1. Isogenic cell panels expressing individual ADAM15 wildtype and catalytically inactive isoforms in 
MDA-MB-231 and MCF-7 cells. (a) Schematic representation of ADAM15 ICD variants. Proline-rich regions 
are boxed. (b) Expression of ADAM15 isoforms in MDA-MB-231 cells, (c) MDA/ADAM15 C and D cells 
treated with 50 µM Decitabine for 72hrs, each 24 hr replacing the media and adding Decitabine fresh. For the 
last 24hrs, 500 nM Trichostatin A was added, followed by analysis for ADAM15 expression. (d) Expression level 
of ADAM15 isoforms in MCF-7 cells.
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ADAM15 isoform-dependent up-regulation of Claudin-1 in breast cancer cells. To test whether 
ADAM15-dependent changes in cell morphology involved reversal of the mesenchymal phenotype of the 
MDA-MB-231 cells to a more epithelial phenotype, we analysed the expression of cell-cell junction molecules and 
Figure 2. Expression of ADAM15 isoforms affects the morphology of breast cancer cells. (a) Phase-contrast 
images of ADAM15 isoform expressing MDA-MB-231 cells, Scale bar = 100 µm (b) downregulation of 
ADAM15 expression by shRNA to the coding region restores the morphology of MDA-MB-231 cells. Scale 
bar = 100 µm c) cell circularity (n = 150) and (d) cell spread area (n = 150) was quantified with ImageJ by 
analysing the outlines of cells in phase-contrast images. (e) Cell size measured by flow cytometry (n = 3). MDA/
ADAM15 A-E WT expressing cells were compared to the MDA/FRT control cell line. Confidence intervals: 
∗p ≤ 0.05, ∗∗p ≤ 0.01, ∗∗∗p ≤ 0.001, ∗∗∗∗p ≤ 0.0001.
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Figure 3. Expression of ADAM15 isoforms affects the proliferation rate and motility of MDA-MB-231 cells. 
(a) ADAM15 isoform expressing cells were seeded in 96 well plates at 3 × 103 density in triplicates. CellTiter 
96 Aqueous One solution (Promega) was added at 24, 48, 72, and 96 h, and absorbance measured at 450 nm. 
Values for 24 h time point were standardised to 1. Statistical significance was assessed with two-way ANOVA 
and Bonferroni post-test. Confidence intervals: *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; n = 3. (b) 
Representative images of scratch-wound assay at 0, 24 and 48 h. Scale bar = 200 µm. (c) Statistical analysis of 
the scratch wound assay comparing the motility of each ADAM15 isoform with parental MDA-MB-231 cells. 
Statistical significance was assessed with two-way ANOVA and Bonferroni post test. Confidence intervals: 
*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.001; n = 3.
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Epithelial Mesenchymal Transition (EMT) markers. Expression of vimentin, slug, or E-cadherin (Supplementary 
Fig. 3) were unchanged in WT ADAM15A and ADAM15A E349 mutant expressing cells, demonstrating that 
ADAM15A does not cause mesenchymal-epithelial transition in MDA-MB-231 cells.
However, analysis of tight junction proteins revealed significant upregulation of Claudin-1 expression in 
WT ADAM15A and, to some degree, in WT ADAM15C and E expressing MDA-MB-231 cells (Fig. 4a) and 
predominantly in WT ADAM15E expressing MCF7 cells (Fig. 4b). These changes were not apparent in cells 
expressing the catalytically inactive ADAM15 isoforms, indicating that metalloproteinase function is necessary 
for ADAM15-mediated induction of Claudin-1. We did not observe significant changes in the expression of other 
tight junction molecules such as ZO1, ZO2 and occludin in either cell panel (Fig. 4c and not shown). Taqman 
qPCR analysis of mRNA confirmed that Claudin-1 up-regulation is at the transcriptional level (Supplementary 
Fig. 4).
Next we sought to investigate if claudin-1 expression depends on ADAM15 overexpression. In 
ADAM15A-expressing MDA-MB-231 cells, shRNA-mediated knockdown of ADAM15A led to reduced expres-
sion of Claudin-1 compared to levels seen in control MDA/ADAM15A/sh-NT cells (Fig. 4d, left panel), indicat-
ing that ADAM15 is necessary for Claudin-1 up-regulation in MDA-MB-231 cells. To confirm this further we 
made use of T47D breast cancer cells that have high expression levels of endogenous ADAM15 isoforms A, C and 
E (Supplementary Fig. 5), as well as of Claudin-1. Introduction of shRNA targeting the 3′UTR of ADAM15 into 
T47D cells down-regulated endogenous ADAM15 expression, leading to a concomitant decrease in Claudin-1 
levels confirming that ADAM15 is responsible for driving Claudin-1 expression in these breast cancer cells.
To test the potential role of the elevated Claudin-1 expression in response to ADAM15A over-expression in 
regulating transepithelial electrical resistance (TEER), paracellular permeability, or cell migration, we transfected 
ADAM15A-overexpressing cells with Claudin-1 shRNA or non-targeting controls. Supplementary Fig. 6a shows 
that significant reduction of Claudin-1 expression was achieved. Subsequently cells were used to measure TEER, 
paracellular permeability and migration using the scratch wound assay. With respect to TEER and paracellular 
permeability, no significant differences were observed between MDA-MB-231/ADAM15A/sh-nontarget cells 
compared with MDA-MB-231/ADAM15A/sh-ADAM15 or MDA-MB-231/ADAM15A/sh-Claudin-1 cells, or 
between T47D/sh-nontarget or T47D/sh-ADAM15 (Supplementary Fig. 6b). Likewise, comparison of wound 
healing rates between MDA-MB-231/ADAM15A/sh-nontarget and MDA-MB-231/ADAM15A/sh-Claudin-1 
cells (Supplementary Fig. 6c) showed no difference in wound closure, suggesting Claudin-1 has no role in regu-
lating the speed of cell migration in these cells.
The PI3K/mTOR pathway is involved in upregulating Claudin-1 expression downstream of 
ADAM15. Several signalling pathways have been implicated in regulating Claudin-1 expression18–22. An ini-
tial screen of various pathway inhibitors allowed us to exclude PKC isoforms, Src family and MAPK involvement, 
while indicating a potential role for PI3K signalling pathway as a regulator of Claudin-1 expression downstream 
of ADAM15 (Supplementary Fig. 7). This prompted us to analyse the role of PI3K effector mTOR. Protein levels 
of Claudin-1 in MDA/ADAM15A, C and E expressing cells in response to two different specific pharmacological 
inhibitors of PI3K and mTOR showed moderate decreases (Fig. 5a), though cyclohexamide treatment indicates 
that Claudin-1 protein is stable for the duration of the assay in MDA/ADAM15A cells (Supplementary Fig. 8). The 
treatments did not affect ADAM15 expression (Supplementary Fig. 9). However, analysis of Claudin-1 mRNA 
levels following PI3K and mTOR inhibition confirmed their role in upregulating Claudin-1 expression down-
stream of ADAM15 (Fig. 5b). Additionally, PI3K inhibition by LY294002 for 24 hrs led to re-establishment of 
the spindle-like mesenchymal morphology in ADAM15A expressing cells as demonstrated in the phase-contrast 
images (Supplementary Fig. 10), while only moderated changes were observed in ADAM15C and E isoform 
expressing cells.
ADAM15 co-localises with Claudin-1 and ZO1 at cell-cell junctions and is in a complex with 
ZO1. Aberrant expression and mis-localisation (cytoplasmic/nuclear instead of cell-cell junctions) of 
Claudin-1 is reported in several cancers, such as osteosarcomas and colorectal cancers23,24. Since ADAM15A iso-
form expressing cells grow in epithelial-like islands, we anticipated that Claudin-1 would be localised to cell-cell 
junctions. Immunofluorescence analysis (Fig. 6a) revealed that Claudin-1 is localised predominantly at cell-cell 
junctions, and at the cell periphery, and co-localises with ADAM15. Immunofluorescence analysis of endogenous 
Claudin-1 and ADAM15 in T47D breast cancer cells also demonstrated Claudin-1 and ADAM15 co-localisation 
at cell-cell junctions and the cell periphery (Fig. 6c). These data suggest that ADAM15 and Claudin-1 might be in 
a protein complex. ADAM15 ICD interacts with SH3 domain-containing cytoplasmic proteins via its proline-rich 
regions, and SH2 domain containing proteins via phosphorylated tyrosines4,5,25. Claudin-1 does not contain SH2 
or SH3 interaction motifs, thus it is unlikely to interact directly with ADAM15. However, Claudin-1 contains a 
PDZ binding motif, with which it forms a complex with SH3 domain containing ZO1. Thus, ZO1 could potentially 
interact with ADAM15 and localise it close to Claudin-1. Indeed, immunofluorescence analysis of ADAM15A 
expressing MDA-MB-231 cells, as well as T47D cells with ZO1 and ADAM15 antibodies (Fig. 6b,d), demon-
strated co-localisation of ADAM15 and ZO1 at cell-cell junctions, as well as the cell periphery in both cell lines. 
Claudin-1, as well as ZO1, demonstrated characteristic cell-cell junction localisation in A431 cells (Fig. 6a,b). 
Further immunoprecipitation analysis with either V5 (Fig. 6e) or ZO1 (Fig. 6f), or ZO2 (Supplementary Fig. 11), 
revealed that ZO1, ZO2 and all but one ADAM15 isoform (ADAM15D) co-immunoprecipitate, suggesting that 
ZO1 and ZO2 are likely interacting partners of ADAM15. The lack of co-IP between ADAM15D (that does not 
contain proline-rich motifs) and ZO1/2 suggests that ZO1/2-ADAM15 interaction is likely to be mediated via the 
SH3 domain of ZO1/2 and proline-rich regions in ADAM15 ICD.
In the course of Claudin-1 IF analysis small proportion of MDA-MB-231/ADAM15A cells showed positive 
staining for Claudin-1 in the nuclei as shown in Fig. 6g, while there was no appreciable Claudin-1 staining in 
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MDA-MB-231/ADAM15A/shClaudin-1 cells. Subcellular fractionation of cells grown to confluency demon-
strated that Claudin-1 is present not only in the membrane fraction, but low levels were detectable in the cyto-
plasmic as well as nuclear fractions (Fig. 6h).
Figure 4. Expression of some ADAM15 isoforms leads to upregulation of claudin-1 in breast cancer 
cells. (a) Total protein extracts of MDA-MB-231 cells (n = 3) and (b) Total protein extracts of MCF-7 cells 
expressing ADAM15 isoforms grown to near-confluence were analysed for the expression of claudin-1. (c) 
Expression of the tight junction proteins ZO1 (n = 3), ZO2 (n = 1) and occludin (n = 5) in MDA/ADAM15 
isoform expressing cells. (d) Stable downregulation of ADAM15 either by an shRNA to the coding region in 
MDA-MB-231 ADAM15A expressing cells or by an shRNA to the 3′UTR in T47D cells leads to a decrease in 
claudin1 expression. Dunnett’s multiple comparison test was carried out to assess significance. Confidence 
intervals: *p < 0.05; **p < 0.01; ***p < 0.001.
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Discussion
Elevated expression of ADAM15 has been observed in numerous cancer types including breast5,26,27, prostate27–29, 
bladder30 and lung31. Indeed ADAM15 has recently been identified in a large genome-wide association study 
of over 60,000 cancers in multiple sites as a locus with pleiotropic associations with breast and lung cancer32. 
In breast cancer, particular ADAM15 variants that result from alternative splicing of exons encoding the ICD 
have different functional consequences in relation to patient outcomes and shedding of FGFR2iiib5,12. How indi-
vidual ADAM15 isoforms contribute to contrasting breast cancer prognosis has been unclear so far. To bet-
ter understand the functional consequences of the overexpression of each isoform, we generated isogenic cell 
panels expressing individual ADAM15 isoforms in their wild type and catalytically inactive forms. The studies 
reported here reveal ADAM15 variant-specific effects on cell morphology, size, spread, as well as proliferation and 
migration. Moreover, the investigation also revealed ADAM15 variant-specific and catalytic activity-dependent 
Figure 5. PI3K/mTOR signalling pathway is involved in upregulating claudin1 expression downstream of 
ADAM15 in MDA-MB-231 cells. Cells were treated with inhibitors of PI3K LY294002 (50 µM), PI-103 (1 µM), 
and of mTOR Rapamycin (100 nM) and Ku0063794 (1 µM) overnight. (a) Protein extracts were analysed for 
Claudin-1 expression. Statistical significance was assessed by two-way ANOVA. The inhibitor treatment was 
compared to the vehicle control for MDA/ADAM15 A, C and E expressing isoforms individually. Confidence 
intervals: ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001. n = 3 Phosphorylation of ribosomal protein S6 was used as a 
readout for PI3K/mTOR activity. (b) RT-PCR analysis of Claudin-1 expression. Quantification of Claudin-1 
expression normalised with GAPDH. n = 3.
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Figure 6. Complex formation between Claudin-1, ZO1 and ADAM15 in MDA-MB-231 and T47D cells. 
Co-localisation of overexpressed ADAM15 (V5, AlexaFluor-488, green) and (a) Claudin-1 (AlexaFluor-594, 
red) or (c) ZO1 (AlexaFluor-594, red) in MDA/ADAM15 A expressing cells. MDA/FRT and A431 cells do 
not contain V5 tagged ADAM15 and serve as negative control for V5. A431 were used as positive control 
for claudin-1cell-cell junction localisation. Co-localisation of ADAM15 (AlexaFluor-488, green) with (c) 
Claudin-1 (AlexaFluor-594, red) or (d) ZO1 (AlexaFluor-594, red) in T47D cells. Example areas of co-
localisation are highlighted with arrows. Scale bar = 10 mm. Immunoprecipitation of (e) ADAM15 (V5) and 
(f) ZO1 from MDA/ADAM15 A-E expressing cells. V5 IP probed with V5, Grb2 (as a positive control for 
co-IP with ADAM15) and ZO1. ZO1 IP probed with ZO1 and V5. (g) Representative IF images of Claudin-1 
localisation to nuclei in MDA/ADAM15A cells. ADAM15 (ADAM15-ECD, AlexaFluor-594, red) and claudin1 
(AlexaFluor-488, green) localization in MDA/ADAM15A, MDA/ADAM15A/sh-non-target and MDA/
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upregulation of the expression of the tight junction protein Claudin-1, which may help to explain some aspects of 
the actions of ADAM15 in breast cancer.
ADAM15 isoform expression led to changes in the growth rate of MDA-MB-231 cells. The expression of all 
but ADAM15B isoform led to reduction in the growth rate of these cells. However, the catalytic activity of only 
ADAM15C isoform was necessary for the observed reduction. ADAM15 isoform expression led to changes in the 
motility of MDA-MB-231 cells. Overexpression of ADAM15 A-D isoforms reduced the motility of these cells over 
the analysed 48 hr period. This is unlikely to be the result of reduced proliferation, as the decrease in the migration 
rate was significantly apparent within 8hrs (ADAM15 B and C) and 24hrs (ADAM15 A and D) of monitoring, 
while there are no obvious changes in the proliferation rate in the first 48hrs of monitoring. ADAM15D overex-
pression had the most pronounced effect, with the wounds not closing up to 96hrs (data not shown). On the other 
hand, overexpression of ADAM15E had no effect on the motility. Detailed analysis of how ADAM15 isoforms 
effect cell motility are currently underway in our group.
Claudin-1 upregulation downstream of ADAM15 depends on the catalytic activity of ADAM15, as the expres-
sion of catalytically inactive E349A isoforms do not lead to significant Claudin-1 expression. Given that ADAM15 
has been reported as an ectodomain sheddase for a variety of transmembrane proteins including EGFR ligands8, 
E-cadherin9, CD237, MICB10, FGFR2iiib12, we hypothesise that ADAM15 isoforms shed distinct membrane teth-
ered ligands that activate their cognate transmembrane receptors, activating intracellular signalling pathways 
affecting gene expression. We screened a panel of pharmacological inhibitors to a number of intracellular signal-
ling pathways that have either been implicated in regulating Claudin-1 expression, or the components have been 
shown to interact with ADAM15 ICD. This established that the PI3K/Akt pathway is required downstream of 
ADAM15 isoform action to mediate Claudin-1 upregulation, while PKC, MAPK and Src family tyrosine kinase 
activities were not essential.
The PI3K/Akt/mTOR pathway regulates a variety of cellular functions in cancer, such as cell growth, survival, 
proliferation. PI3K, as well as mTOR, are activated downstream of a number of cell surface receptors. While 
there is evidence that ADAM15 associates with the p85 regulatory subunit of PI3K25 and thus could potentially 
affect PI3K activity, we believe this is not the case here. Our data demonstrate that ADAM15-mediated Claudin-1 
upregulation via PI3K and mTOR depends on the metalloproteinase catalytic function of ADAM15, as there is no 
significant expression of Claudin-1 in cells expressing the catalytically inactive ADAM15. This strongly suggests 
that certain ADAM15 isoforms activate cell surface receptors in an autocrine manner by increasing the availa-
bility of their corresponding ligands through shedding, which then results in PI3K and mTOR activation. We 
observed that the expression of ADAM15 A, C and E isoforms led to significant increase in cell size, as measured 
by FACS analysis, further supporting elevated PI3K/mTOR activity.
This also indicates that at least one common ADAM15A, C and E ICD interacting protein might regulate the 
catalytic activity and/or substrate choice of these isoforms. This is in agreement with our previous data where 
ADAM15B had enhanced proteolytic activity towards FGFR2iiib when interacting with and being phosphoryl-
ated by Src12. Furthermore, we observed that ADAM15C expression reduces the growth rate of MDA-MB-231 
cells in a catalytic function dependent manner. This points that ADAM15C isoform sheds at least one other sub-
strate, which is necessary for the proliferation of MDA-MB-231 cells. This may in part explain why breast cancer 
patients with ADAM15C overexpression have better survival rates5. So far, the functions of ADAM15 have been 
elusive since it has been difficult to identify its substrates. Identification of ADAM15 isoform-dependent shed 
substrates using approaches such as TMT-MS-TAILS33,34, will have significant implications for cancer patients, 
as well as for advancing our understanding of the role of ADAM15 splicing for cancer biology and progression.
Claudin-1 is a barrier forming tight junction protein, its expression generally ensuring decreased permea-
bility. There is conflicting evidence of the role of ADAM15 in regulating permeability in a number of studies. 
Earlier work35,36 proposed that ADAM15 functions as a cell adhesion molecule, enhancing cell-cell interactions to 
decrease permeability in NIH3T3 cells, and that the surface expression of ADAM15 in HUVECs can be driven by 
VE-cadherin, leading to localisation of ADAM15 at adherens junctions. This concurs with our data demonstrat-
ing ADAM15 presence in cell-cell adhesions. However, in MDA-MB-231 cells, ADAM15 localisation to cell-cell 
junctions was isoform-dependent, with ADAM15A isoform showing the most prominent junctional localisation, 
and ADAM15B isoform not localising to cell-cell junctions even in over-confluent cultures.
Sun et al.15 demonstrated a requirement for ADAM15 for endothelial hyper-permeability and increased neu-
trophil transmigration in response to thrombin exposure. This was independent of ADAM15 protease activity, 
but required signalling via Src and Erk1/2. Additionally, these authors showed ADAM15 to be necessary for 
LPS-induced endothelial hyper-permeability and neutrophil transmigration in the lung37. On the other hand, 
expression of miR-147b improved human lung endothelial barrier function by down-regulating ADAM1538. 
These studies support the notion that while constitutive expression of ADAM15 might not be a determinant of 
basal endothelial barrier properties, it plays an active role in mediating endothelial hyper-permeability and neu-
trophil transmigration under inflammatory conditions. However, these effects of ADAM15 on endothelial barrier 
permeability have not been linked to altering the expression of tight junction related proteins such as Claudin-1. 
Moreover, our data show that the expression of ADAM15 in either MDA-MB-231 or MCF7 cells did not lead 
to changes in cell monolayer permeability, and the measurement of trans-epithelial resistance did not show sig-
nificant differences in MDA-MB-231 cells with or without ADAM15 or Claudin-1 expression. Thus ADAM15 
ADAM15A/shClaudin1 expressing cells. Nuclei visualized by DAPI (blue). Scale bar = 10 µm. (h) Subcellular 
localization of claudin-1 by fractionation analysis of MDA/ADAM15A expressing cells. HSP90 serves as 
cytoplasmic, R-cadherin as membrane and Lamin A/C as nuclear control. T = Total cell lysate; C = cytoplasmic 
fraction; M = Membrane fraction; N = Nuclear fraction.
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appears to have different effects on endothelial versus epithelial permeability, which is unsurprising, considering 
its pleiotropic functions in different cells and tissues.
There is growing evidence that certain tight junction proteins have more than junctional functions, as their 
overexpression or mislocalisation can contribute to cancer progression by enhancing cell survival, invasion and 
metastasis (reviewed in Leech 201539). Specifically, the increased expression of Claudin-1 in colon cancer corre-
lated with metastasis and poor prognosis40–42, and with poor outcome in high grade invasive ductal carcinoma of 
the breast where it correlated with the molecular subtype43. Tamoxifen treatment of MCF7 cells has been shown 
to lead to Claudin-1 overexpression that antagonises apoptosis and promotes drug resistance44. Additionally, 
expression of Claudin-1 provided resistance to anoikis in gastric and colon cancer cells45,46, as well as resistance 
to apoptosis in nasopharyngeal carcinoma cells47. Moreover, upregulation of Claudin-1 in ovarian carcinoma 
effusions has been associated with poor survival48.
As ADAM15A expressing MDA-MB-231 cells maintain strong cell-cell adhesions, it is possible to hypoth-
esize that the expression of ADAM15A may lead to enhanced collective cell migration. Although aberrant 
expression of Claudin-1 in cancers has been implicated in promoting collective cell migration49, the role of 
ADAM15A-mediated Claudin-1 overexpression in MDA-MB-231 cells in collective cell migration remains to be 
elucidated. Nevertheless, the stable silencing of Claudin-1 in these cells did not lead to the disassembly of cell-cell 
junctions, nor did it alter the speed of cell migration.
Interestingly, we observed that in a small proportion of MDA-MB-231/ADAM15A cells, that have not formed 
the epithelial-like islands, Claudin-1 was localised to nuclei. This is very much in agreement with Fortier et al.49, 
where the cells at the leading edge of the migratory sheets have nuclear and cytoplasmic Claudin-1 localisation, 
while in the following cells it is localised in the cell-cell junctions, maintaining cohesion. Nuclear Claudin-1 
expression has also been observed in metastatic lesions in colon cancer24, in nasopharyngeal cancer cells47, oste-
osarcoma cells23, in follicular thyroid carcinoma cells and FTC metastasis50.
Claudin-1 is overexpressed in hepatocytes, and is one of the major homing receptors for Hepatitis C virus51. 
It is tempting to speculate that ADAM15 mediated Claudin-1 upregulation might have a role in defining the 
metastatic niche, enhancing breast cancer cell attachment to hepatocytes and metastasis to the liver. Interestingly, 
SW480 colon cancer cells engineered to overexpress Claudin-1 formed tumors at a significantly higher rate and 
caused multiple liver metastases compared with the control cells24.
Amongst the ADAM family, ADAM15 isoforms have the widest range of ICD interaction partners identified 
so far. It will be important to identify which particular intracellular interactions lead to substrate selection for the 
isoform-specific catalytic function of ADAM15. Here we identified that the ZO family proteins also form com-
plexes with ADAM15. This is in line with a recent study identifying ZO1 as an interaction partner of ADAM1252. 
ADAM15 isoforms A, C and E co-localised with ZO1 as judged by immunofluorescence analysis. Additionally, all 
ADAM15 isoforms, except ADAM15D, and ZO1 and ZO2 co-immunoprecipitated. Together, this suggests that 
the ADAM15 interaction with ZO1/2 is likely to be direct, involving the proline-rich regions in ADAM15 and the 
SH3 domains in ZO proteins.
In summary, our data show that ADAM15 expression in breast cancer cells leads to upregulated expression 
of the tight junction protein Claudin-1, which involves activation of the PI3K/mTOR pathway. The increased 
Claudin-1 expression is ADAM15 isoform-specific and catalytic activity-dependent, as well as influenced by the 
cell background based on the differences we observed between MDA-MB-231 and MCF-7 cell lines. We con-
firmed the dependence of Claudin-1 on ADAM15 in T47D cells, which express high endogenous levels of both 
proteins. ADAM15 also co-localizes with Claudin-1 at cell-cell junctions, potentially via the association of ZO1/2 
SH3 domains with the ADAM15 ICD. These associations provide new insights into the mechanisms by which 
ADAM15 contributes to progression of breast and other cancers, highlighting in particular the significant differ-
ences between the ICD variant forms of ADAM15.
Data Availability
All data generated or analysed during this study are included in this published article [and its Supplementary 
Files].
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